PG
GNMK

PEAK6 Group’s GenMark Diagnostics, Inc GNMK Stock Holding History

PEAK6 Group’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-29,600
Closed -$230K – 5261
2015
Q4 		$230K Hold
29,600
– – ﹤0.01% 3335
2015
Q3 		$233K Buy
+29,600
New +$274K ﹤0.01% 3604

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PEAK6 Group's GNMK Position: Q1 2016 in Review

PEAK6 Group sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2016, closing a stake of 14,723 shares — an estimated $114K sold.

PEAK6 Group first reported a position in GNMK in Q3 2015 and held it in 2 quarters. The position peaked at $138K in Q3 2015. 86 funds tracked by Wall St. Rank hold GNMK as of Q1 2016.

  • PEAK6 Group reported no remaining GenMark Diagnostics, Inc position as of Q1 2016 after selling out during the quarter.
  • PEAK6 Group sold 14,723 GenMark Diagnostics, Inc shares in Q1 2016, an estimated $114K.
  • PEAK6 Group first reported a position in GenMark Diagnostics, Inc in Q3 2015 and held it in 2 quarters.
  • PEAK6 Group's GenMark Diagnostics, Inc position peaked at $138K in Q3 2015.
  • 86 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2016.

Based on PEAK6 Group's 13F filing for Q1 2016, filed 13 May 2016.